{"version":"1.0","type":"link","title":"POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.","author_name":"Vachhani P 외","author_url":"https://prs-insight.online/author/Vachhani%20P","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/160796","thumbnail_width":1200,"thumbnail_height":630}